comparemela.com
  1. Home
  2. Live Updates
  3. Point Therapeutics - Breaking News

Latest Breaking News On - Point therapeutics - Page 1 : comparemela.com

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomAleena gandhiPoint therapeuticsChief medical officer

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 20, 2024

United statesUnited kingdomAleena gandhiPoint therapeuticsChief medical officerBusiness wire

Bristol-Myers Squibb (BMY) Announces FDA Acceptance for Priority of Application for Augtyro

Bristol-Myers Squibb (BMY) Announces FDA Acceptance for Priority of Application for Augtyro
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibbJoseph fioreDrug administrationBristol myers squibb companyNew drug applicationPriority reviewPrescription drug user fee actBristol myersMyers squibbPoint therapeutics

U S Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors | Region

PRINCETON, N.J. (BUSINESS WIRE) Feb 14, 2024

Joseph fioreBristol myers squibbBristol myers squibb companyDrug administrationExchange commissionMyers squibbNew drug applicationPriority reviewPrescription drug user fee actBristol myersPoint therapeuticsResponse evaluation criteriaSolid tumorsBlinded independent central reviewPositive solidBetter future

FDA Grants Priority Review to Repotrectinib for NTRK+ Solid Tumors

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

Joseph fioreRepotrectinib augtyroBristol myers squibbDrug administrationPoint therapeutics incEuropean medicines agencyVirtual congressNew drug applicationBristol myersPrescription drug user fee actTyrosine kinase inhibitorMedicines agencyUpdated novemberPoint therapeuticsPriority reviewNtrk positive locally advanced or metastatic solid tumors

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.